Clin2
NCT06701669Possibly a fitRecruiting

Study of Paridiprubart for moderate to severe ARDS

Acute Respiratory Distress Syndrome (ARDS)ARDSARDS (Acute Respiratory Distress Syndrome)Acute Respiratory Distress Syndrome

Part of Lungs & breathing clinical trials.

This trial tests a new medicine called paridiprubart to see if it can help people with moderate or severe acute respiratory distress syndrome (ARDS), a serious lung condition. It may be an option if you have low oxygen levels and no known allergy to the drug.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have moderate or severe ARDS, meaning your oxygen levels are very low.
  • You do not have a known allergy to paridiprubart or ingredients like polysorbate 80.
  • You do not have severe liver damage (cirrhosis with a score of 12 or higher).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06703073Recruiting· Phase 2
Testing new treatments for acute respiratory distress syndrome (ARDS)

This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.

Birmingham, Alabama
NCT06701656Recruiting· Phase 2
Testing bevacizumab for breathing problems from ARDS

This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.

Birmingham, Alabama
NCT06701682Recruiting· Phase 2
Study of vilobelimab for moderate to severe ARDS

This trial tests a drug called vilobelimab for people with moderate or severe ARDS (a serious lung condition). It aims to find if this treatment can help improve breathing and outcomes.

Birmingham, Alabama
NCT05075161Recruiting· Phase 3
Pirfenidone to help prevent lung scarring in ARDS

This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.

Milan, MI
NCT07186140Not yet recruiting
Acute respiratory distress syndrome (ARDS) study: treatments and outcomes

This trial observes the symptoms, treatments, and recovery of patients with acute respiratory distress syndrome (ARDS), a serious lung condition. It aims to learn more about how different types of breathing support affect outcomes.

Seoul
NCT06640777Not yet recruiting· Phase 3
Testing a new drug for severe lung injury

This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.

Paris, Paris

Hear when a new ARDS trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.